BioNexus Gene Lab 株価情報 (NASDAQ: BGLC)

最新ニュース BioNexus Gene Lab (NASDAQ:BGLC) 株価情報

BioNexus Gene Lab

BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.

BioNexus Gene Lab Corp

WIIM

SONM

Sonim Technologies shares are trading lower after the company announced the pricing of a $5.55 million offering of 7,400,000 shares at $0.75 per share.

Wells Fargo analyst Colin Langan maintains Adient (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADNT#NYSE">ADNT</a>) with a Equal-Weight and raises the price target from $17 to $18.

News

Price Target

Analyst Ratings

ADNT

Wells Fargo Maintains Equal-Weight on Adient, Raises Price Target to $18

Offerings

Sonim Technologies Prices $5.55M Public Offering Of 7.4M Shares At $0.75/Share

Wells Fargo analyst Elyse Greenspan maintains Unum Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNM#NYSE">UNM</a>) with a Overweight and raises the price target from $97 to $105.

Wells Fargo Maintains Overweight on Unum Gr, Raises Price Target to $105

Macro Economic Events

Econ #s

Economics

USA Redbook (YoY) 4.9% Vs 4.5% Prior

HSDT

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Wedbush analyst Daniel Ives reiterates Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Outperform and maintains $500 price target.

Reiteration

TSLA

Wedbush Reiterates Outperform on Tesla, Maintains $500 Price Target

Wedbush analyst Dan Ives predicts a weak performance for Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) amidst a fallout between CEO Elon Musk and President Donald Trump.
What Happened: On Tuesday, Ives posted on X his prediction about Tesla&#8217;s performance, attributing it to the strained relationship between Musk and Trump. He described the situation as a &#8220;junior high school friendship gone bad.&#8221; However, he added that it would eventually stabilize.
&#8220;At the end of the day Musk needs Trump and Trump needs Musk. Will settle down,&#8221; posted Ives.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Tesla to be weak this morning as the Street will show concern that the Trump and Musk once BFF relationship now backfires and turns into a junior high school friendship gone bad into an enemy. At the end of the day Musk needs Trump and Trump needs Musk. Will settle down &#x1f94a;&#x1f91d;
&mdash; Dan Ives (@DivesTech) <a href="https://twitter.com/DivesTech/status/1940022572625600815?ref_src=twsrc%5Etfw">July 1, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
SEE ALSO: <a href="https://benzinga.com/markets/macro-economic-events/25/07/46187826/mike-pences-advocacy-group-launches-campaign-to-extend-trumps-2017-tax-cuts-report" target="_blank" rel="noreferrer noopener">Mike Pence&#8217;s Advocacy Group Launches Campaign To Extend Trump&#8217;s 2017 Tax Cuts: Report</a>
Why It Matters: The relationship between Musk and Trump has been a topic of interest recently. Trump has been vocal about the subsidies Musk&#8217;s companies receive, suggesting that without them, Musk would have to &#8220;close up shop and head back home to South Africa.&#8221;
This public criticism by Trump has had an impact on Tesla&#8217;s stock. Following Trump&#8217;s comments, Tesla&#8217;s stock fell by <a href="https://www.benzinga.com/markets/tech/25/07/46189226/tesla-stock-falls-nearly-5-in-tuesday-pre-market-whats-going-on">nearly 5% </a>during the Tuesday pre-market session. Musk&#8217;s response to Trump&#8217;s spending bill also reignited political comeback rumors, further affecting the stock.
Investment advisor Ross Gerber criticized Tesla&#8217;s board for remaining silent amid the Trump-Musk Feud and the federal subsidies. He suggested that Musk&#8217;s enabling of Trump&#8217;s presidency would eventually lead to a power struggle.
<ul class="wp-block-list">
<li>READ MORE: <a href="https://benzinga.com/crypto/25/06/46186644/bitcoin-ethereum-dogecoin-slide-even-as-q2-turns-profitable-for-crypto-analyst-warns-about-decline-in-btc-if-the-apex-coin-doesnt-close-above-this-level" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, Dogecoin Slide Even As Q2 Turns Profitable For Crypto: Analyst Warns About Decline In BTC If The Apex Coin Doesn&#8217;t Close Above This Level &#8211; Grayscale Bitcoin Mini Trust (BTC) Common</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Tesla Stock Slump Tied To Trump-Musk 'Junior High School Friendship' Gone Sour, Says Dan Ives — But Predicts It Will 'Settle Down'

Wedbush analyst Daniel Ives reiterates Progress Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRGS#NASDAQ">PRGS</a>) with a Outperform and maintains $75 price target.

PRGS

Wedbush Reiterates Outperform on Progress Software, Maintains $75 Price Target

Wells Fargo analyst Donald Fandetti maintains Synchrony Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYF#NYSE">SYF</a>) with a Overweight and raises the price target from $65 to $75.

Wells Fargo Maintains Overweight on Synchrony Financial, Raises Price Target to $75

HURA

TuHURA Biosciences Added To Russell 3000 Index, With Automatic Inclusion In Russell 2000 Index

Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compliance and no impact on survival
2- and 6-week interim safety results demonstrated GRI-0621 to be safe and well-tolerated in the first 12 and 24 patients evaluated, respectively
Results on track for 6-week interim biomarker analysis (n=24) in July 2025 and topline data in Q3 2025
LA JOLLA, CA, July 01, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=baPDKYdp3BSWHP45JArGos_yUZqEn9JWMuXvfBdwYAxdL6IgP7Iji95uzky4X6ZrOY7DGAUopvYZfr1F87uU4g==">GRI Bio, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the completion of patient enrollment for its Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis ("IPF").

Biotech

General

ALPS ETF Trusthen & Steers Global Realty Majors ETF

GRI Bio Completes Enrollment In Phase 2a Trial Of GRI-0621 For Idiopathic Pulmonary Fibrosis; 2- And 6- Week Interim Safety Results Demonstrated GRI-0621 To Be Safe And Well-Tolerated In The First 12 And 24 Patients Evaluated, Respectively

New Era Helium, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEHC#NASDAQ">NEHC</a>) ("NEH" or the "Company"), a next-gen exploration and production platform in the Permian Basin, today announced that Texas Critical Data Centers LLC ("TCDC"), NEH's joint venture with Sharon AI, signed a non-binding Letter of Intent ("LOI") with a leading global provider of High Performance Cloud for AI and Modern Workloads, marking a major milestone in NEH's digital infrastructure strategy within the Permian Basin.
Under the terms outlined in the LOI, the joint venture contemplates the acquisition of land and a power purchase agreement for up to 250 megawatts of behind-the-meter electricity, purpose-built to support advanced data center operations and next generation compute infrastructure.

NEHC

New Era Helium's JV TCDC Signs Non-Binding LOI With Global Provider Of High Performance Cloud For AI And Modern Workloads For 250MW AI Data Center JV In Permian Basin

A federal court has sided with the U.S. Department of Health and Human Services (HHS), rejecting Johnson &amp; Johnson&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) effort to reshape its participation in the <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">340B Drug Pricing Program</a>.
The ruling comes after months of legal back-and-forth following Johnson &amp; Johnson's proposal to shift from upfront drug discounts to a rebate model—an approach the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40560227/johnson-johnson-aims-new-policy-for-hospital-payments-under-340b-drug-discount-program-related-to" rel="noreferrer noopener">agency never formally approved</a>.
The dispute centers on the 340B Program, a federal initiative requiring pharmaceutical manufacturers that participate in Medicaid and Medicare Part B to sell outpatient drugs at reduced prices to certain healthcare providers, including hospitals and clinics that serve low-income and rural populations.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/fda/25/06/46166652/fda-eases-access-to-life-saving-gene-therapies-for-blood-cancers" rel="noreferrer noopener">FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers</a>
Johnson &amp; Johnson, a long-time participant in the program, initiated litigation in November 2024 after the Health Resources and Services Administration (HRSA) declined to approve its proposed rebate structure.
Under Johnson &amp; Johnson&#8217;s plan, covered entities would pay the full list price for certain drugs and receive rebates later.
The company contacted HRSA in June 2024 to outline the plan, but the agency made clear it had not given the green light.
Despite this, Johnson &amp; Johnson <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41941391/johnson-johnson-challenges-government-drug-pricing-dispute-over-two-drugs" rel="noreferrer noopener">proceeded to file suit</a> against HHS, HRSA, and their respective leadership, arguing that HRSA's rejection was arbitrary under the Administrative Procedure Act (APA).
In January 2025, UMass Memorial Medical Center, Genesis HealthCare System, and the advocacy group 340B Health were granted permission to intervene in the case as defendants, <a target="_blank" href="https://sponsors.aha.org/rs/710-ZLL-651/images/20250627_340B_045111473084.pdf?version=0" rel="noreferrer noopener">arguing</a> the rebate model would undercut the purpose of the 340B program and impose financial strain on safety-net providers.
Johnson &amp; Johnson subsequently moved for summary judgment on its single APA claim, while both the federal agencies and the intervenors filed cross-motions. The court has now denied Johnson &amp; Johnson's motion and ruled in favor of HHS and the intervenors, concluding that the agency acted within its authority and did not violate administrative law in rejecting the rebate plan.
The decision marks a significant win for hospitals and healthcare groups reliant on upfront 340B pricing to manage drug costs, especially for vulnerable patient populations. It also affirms HRSA's oversight authority in maintaining the integrity of the 340B program.
In sum, based on the plain and unambiguous language of the 340B statute, and supported by its purpose and history, HRSA has the authority to "provide" for discounts, rebates, or both. This conclusion defeats J&amp;J's claim that HRSA lacked the authority to require prior approval of J&amp;J's rebate model, the lawsuit alleged.
Price Action: JNJ stock is up 0.10% at $152.91 during the premarket session at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46021366/mark-cuban-corrects-elizabeth-warren-as-she-slams-jnj-pfe-for-higher-prices-and-zero-taxes-on-big-pharma-pbms-corrupt-healthcare" target="_blank" rel="noreferrer noopener">Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: &#8216;PBMs Corrupt Healthcare&#8217;</a></li>
</ul>
Photo: Shutterstock

Large Cap

Health Care

Legal

Johnson & Johnson's Drug Discount Plan Gets Thrown Out In Court

<a href="https://x.com/rachelvscott/status/1940021740677034098" title="https://x.com/rachelvscott/status/1940021740677034098">https://x.com/rachelvscott/status/1940021740677034098</a>

Politics

Senior Political Correspondent Covering The White House And Congress For ABC Rachel Scott Posts On X "NEW: I just asked the president about his July 4th deadline for Republicans - and whether he's open to moving it back. There are signs he is. 'I'd love to do July 4th but I think it's very hard to do July 4th…. I would say maybe July 4th or somewhere around there.'"

Sagtec Global Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGT#NASDAQ">SAGT</a>) ("Sagtec" or the "Company"), a leading provider of customizable enterprise software solutions, today announced the signing of a US$10 million smart hospitality technology agreement with SMD Tech – FZCO, a UAE-based digital infrastructure firm. This major win represents a pivotal step in Sagtec's expansion strategy across the Middle East and its entry into the high-growth hotel automation segment.
Under the terms of the deal, Sagtec will develop and manage a next-generation Hotel Self Check-In/Out System across premium hospitality properties in the UAE. The project includes software licensing, systems integration, data analytics, and long-term service and maintenance, delivering an end-to-end solution that supports the region's push toward smart tourism and contactless guest experiences.
Contract Breakdown:
<ul>
<li>US$4 million – Licensing and custom software development</li>
<li>US$3 million – Five-year service and maintenance agreement</li>
<li>US$3 million – Five-year data hosting and analytics contract &nbsp;</li>
</ul>
Over 60% of The Contract Value Represents Multi-Year Recurring Revenue Streams
This latest development builds upon Sagtec's May 2025 announcement of a US$30 million revenue pipeline stemming from the exclusive distribution of its Speed+ Smart Ordering System. The UAE partnership diversifies Sagtec's SaaS verticals beyond Food &amp; Beverage into the rapidly growing hospitality tech domain.

Global

SAGT

Sagtec Global Signs $10M UAE Smart Hospitality Tech Deal To Expand Middle East Presence And Enter Hotel Automation Market

On Monday, Mesoblast Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) announced alignment with the U.S. Food and Drug Administration (FDA) on items required for filing a Biologics License Application (BLA) for Revascor (rexlemestrocel-L) for ischemic heart failure with reduced ejection fraction <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">(HFrEF) and inflammation</a>.
In follow-up to the successful Type B meeting in early 2024 under the existing Regenerative Medicine Advanced Therapy (RMAT) designation for Revascor in end-stage HFrEF patients with a left ventricular assist device (LVAD), where the FDA stated that the results of the presented studies could support accelerated approval, Mesoblast met with FDA on June 3, 2025 to align <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g46185666/mesoblast-and-fda-align-on-key-items-for-revascor-biologic-license-application-in-ischemic-heart-f" rel="noreferrer noopener">on key items for BLA filing</a>.
The FDA provided formal minutes to the company following the most recent Type B meeting. The minutes confirm alignment with FDA on chemistry, manufacturing &amp; controls (CMC) items, potency assays for commercial product release, and proposed design and primary endpoint for the confirmatory trial post-approval.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42572083/mesoblasts-cell-therapy-treatment-for-graft-versus-host-disease-gets-fda-approval-stock-surges" rel="noreferrer noopener">Mesoblast&#8217;s Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges</a>
Mesoblast intends to file for accelerated approval in patients with end-stage ischemic HFrEF implanted with an LVAD by the end of the year.
In other recent developments, Mesoblast received seven years of orphan-drug exclusive approval from the FDA for Ryoncil (remestemcel-L) for steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 <a href="https://www.benzinga.com/pressreleases/25/05/g45426923/fda-provides-seven-years-of-orphan-drug-exclusive-approval-for-ryoncil" target="_blank" rel="noreferrer noopener">months of age and older in May</a>.
This period of statutory exclusivity means that the FDA will not approve another mesenchymal stromal or stem cell (MSC) products for this indication during the 7 years from the approval of Ryoncil.
Separately, Mesoblast has biologic exclusivity preventing another sponsor from referencing the Ryoncil biologic license application (BLA) until December 2036, twelve years from its first approval which would prevent market entry by a biosimilar.
These statutory exclusivities, in addition to Mesoblast&#8217;s strong U.S. intellectual property position on MSC composition of matter, manufacturing, and indications, including SR-aGvHD, provide a commercial barrier to entry against competitors through 2044.
In early July, Mesoblast will meet with the FDA to discuss a pivotal trial of Ryoncil in <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45896452/mesoblast-maintains-momentum-with-fda-on-accelerated-approval-pathway-for-revascor-in-ischemic-hea" rel="noreferrer noopener">adults with SR-aGvHD</a>.
This trial will be conducted with the NIH-funded Bone Marrow Transplant Clinical Trials Network (BMT-CTN). The objective is to extend the product&#8217;s label from children to adults with SR-aGvHD.
Price Action: At the last check on Tuesday, MESO stock was up 8.82% at $11.85 during the premarket session.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46189380/nvidias-chinese-rivals-look-to-cash-in-on-us-tech-ban-moore-threads-metax-plot-1-65-billion-ipo" target="_blank" rel="noreferrer noopener">Nvidia&#8217;s Chinese Rivals Look To Cash In On US Tech Ban: Moore Threads, MetaX Plot $1.65 Billion IPO</a></li>
</ul>
Photo by Tada Images via Shutterstock

Movers

Trading Ideas

MESO

Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01010458/Unisound-0620-900x600-2-1.png" alt="" class="wp-image-15111" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01010458/Unisound-0620-900x600-2-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01010458/Unisound-0620-900x600-2-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/01010458/Unisound-0620-900x600-2-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The provider of AI services for a wide range of business customers raised $41 million in its Hong Kong listing, and could raise more in the coming months with secondary share sales

By Doug Young
Unisound AI Technology Co. Ltd.&nbsp;(9678.HK) made its Hong Kong trading debut on Monday, offering investors a new artificial intelligence (AI) choice with a fully integrated product boasting a diverse customer base, speaking to its wide range of potential business users.
The company&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0627/2025062702974.pdf">raised</a>&nbsp;HK$206 million ($26 million) by selling 1.56 million shares for HK$205 apiece, with about a third of those going to three cornerstone investors. The shares for sale represented a relatively small 2.2% of its share capital, suggesting Unisound could sell more stock in one or more secondary offerings in the months ahead if demand is strong.
The stock opened flat at HK$205 when trading began, valuing the company at HK$14.5 billion.
Unisound is one of the older players on China's AI scene, founded more than a decade ago in 2012 by Huang Wei and Liang Jia'en, both of whom come from scientific backgrounds. Backed by strong technological capabilities and its accumulated research in speech recognition and cognitive intelligence, the company has developed dozens of vertically integrated AI products and solutions. These are primarily sold to enterprise clients across sectors such as healthcare and insurance, daily life services, and transportation.
Underpinning its AI services, which help customers run their business processes more efficiently, is Unisound's Atlas Infrastructure, which it began building in 2016. That's the foundation for UniGPT, a proprietary 60 billion-parameter large language model (LLM) that the company launched in 2023. UniGPT is the core algorithm for the company's customer-facing Unibrain central technology platform.
Unisound's revenue grew 29% last year to 939 million yuan ($131 million) from 727 million yuan in 2023. It breaks that figure into two main categories, healthcare and daily life. The daily life segment accounted for about 80% of its revenue last year, covering enterprise clients from the smart mobility and smart living sectors.
Notably, the company's top five customers accounted for just about a quarter of its revenue last year, a relatively low figure. That shows it has a large customer base – a relative rarity among some Chinese AI companies that often rely on just a small number of clients for most of their business.
The company's gross profit margin stood at a relatively high 38.8% last year. But its heavy R&amp;D spending, which is quite common for companies in the AI space, caused its adjusted net loss to widen by 22% last year to 168 million yuan from 137 million yuan in 2023. The company's cash also fell to 156 million yuan by the end of last year, though the new infusion of IPO funds should help as it sets its sights on eventually becoming profitable.
At its IPO price, the company trades at a price-to-sales (P/S) ratio of 14, which looks quite strong compared to some of its Hong Kong-listed peers. By comparison, the larger SenseTime (0020.HK) and Fourth Paradigm (6682.HK) trade at P/S multiples of 12 and 4.3, respectively.

Asia

IPOs

Opinion

Tech

Unisound's IPO offers Investors A New AI Choice

Wells Fargo analyst Jason Haas upgrades Cintas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>) from Underweight to Equal-Weight and raises the price target from $196 to $221.

Upgrades

CTAS

Wells Fargo Upgrades Cintas to Equal-Weight, Raises Price Target to $221

International Business Machines Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) announced on Tuesday an expansion of its relationship with database automation leader DBmaestro, marking a new original equipment manufacturer agreement aimed at strengthening<a href="https://www.benzinga.com/pressreleases/25/07/n46191636/ibm-and-dbmaestro-expand-strategic-oem-partnership-to-deliver-enterprise-grade-database-devops-and" target="_blank" rel="noreferrer noopener"> IBM&#8217;s enterprise DevOps capabilities</a>.
The agreement integrates DBmaestro&#8217;s platform into IBM&#8217;s software portfolio, providing customers with access to robust database DevSecOps tools and advanced observability features.
The partnership builds on IBM&#8217;s previous reseller relationship with DBmaestro and marks a significant milestone in the companies&#8217; collaboration.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/06/46003044/ibms-rally-masks-under-ownership-analyst-sees-further-upside-potential" rel="noreferrer noopener">IBM Stock Remains Under-Owned Despite Rally, Analyst Sees Further Upside Potential</a>
Under this new arrangement, DBmaestro&#8217;s automation technology will become a native element in IBM DevOps solutions including IBM DevOps Loop, Deploy, and Velocity, with further integrations planned across platforms such as IBM Z, HashiCorp Vault, Instana, and more.
Through the OEM partnership, IBM customers can now manage database changes alongside application code, streamlining DevOps workflows. DBmaestro&#8217;s suite offers a range of capabilities, including version control, schema change automation, monitoring, analytics, and error detection, enhancing the end-to-end software delivery lifecycle.
The integration enables faster deployment cycles, tighter compliance controls, and real-time performance tracking.
It also introduces AI-driven insights, helping organizations proactively address errors and implement best practices.
According to DBmaestro CEO Gil Nizri, the joint offering allows enterprises to &#8220;orchestrate flawless software delivery from application code to database deployments.&#8221;
James Hunter, program director at IBM DevOps Automation, emphasized that DBmaestro&#8217;s inclusion will help eliminate one of the final obstacles to complete DevOps integration—databases.
&#8220;This partnership expansion empowers our customers to achieve faster, safer, and more reliable software delivery,&#8221; Hunter said in a statement.
Designed for hybrid and multi-cloud environments, the integrated solution supports agility across complex enterprise IT architectures, further aligning with IBM&#8217;s mission to support digital transformation at scale.
Price Action: IBM shares are trading higher by 0.10% to $295.06 premarket at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46189943/us-stock-futures-slip-after-two-days-of-record-advances-fomo-could-add-another-5-10-says-expert" target="_blank" rel="noreferrer noopener">US Stock Futures Slip After Two Days Of Record Advances: &#8216;FOMO Could Add Another 5%-10%…,&#8217; Says Expert</a></li>
</ul>
Photo: Shutterstock

Equities

Markets

IBM Just Tackled One Of Tech's Most Annoying Bottlenecks

Financing

Press Releases

BioNexus Gene Lab Corp. Completes Strategic RM 1 Million Investment in Ascension Innovation Sdn Bhd

BioNexus Gene Lab Corp. Announces Successful Securities Commission of Malaysia (MyCIF) Co-Investment in Ascension Innovation Sdn Bhd

BioNexus Gene Lab Corp Announces New Business Developments for Subsidiary Chemrex with Investment in High-Quality Color Paste Production

BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and Preventative Healthcare Solutions

Comments

BioNexus Gene Lab

ニュース

最新ニュース BioNexus Gene Lab (NASDAQ:BGLC) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル